GLP-1 Drugs and Pregnancy: Why They're Discontinued Before Conception, Explained

GLP-1 drugs carry a consistent recommendation across prescribing guidance: discontinue before attempting to conceive, with a specific washout period beforehand. Understanding why requires separating what's actually been studied from what simply hasn't.

What the Animal Data Showed

Animal reproductive studies of semaglutide and tirzepatide found evidence of embryo-fetal toxicity and developmental abnormalities at doses relevant to human exposure, which is the primary basis for current pregnancy warnings — this is standard preclinical animal reproductive toxicology testing, required for all new drugs, and a positive finding in this testing category triggers cautious labeling regardless of whether human data exists yet.

Why Human Pregnancy Data Is Limited

Pregnant women are routinely excluded from the clinical trials that support a drug's initial approval, for standard ethical reasons around exposing a fetus to an unproven intervention — this means GLP-1 drugs, like the vast majority of newly approved medications, don't have dedicated randomized human pregnancy safety trials. What exists instead is a small and growing body of observational data from women who conceived while on GLP-1 therapy (often unintentionally, given these drugs' fertility-improving effects in conditions like PCOS) or registries tracking outcomes — this data is accumulating but remains far short of the volume and rigor needed to establish clear human safety, in either direction.

Why the Recommended Washout Period Exists

Because of the animal toxicity signal and the absence of robust human safety data, current guidance recommends discontinuing GLP-1 therapy for a specific period before attempting conception — generally around two months for semaglutide, reflecting the time needed for the drug to clear the body given its multi-week half-life, so that the developing embryo isn't exposed during the critical early developmental window. This washout-before-conception approach, rather than stopping only upon a positive pregnancy test, exists specifically because significant embryonic development occurs in the earliest weeks, often before pregnancy is even confirmed.

The Fertility-Improvement Complication

An added practical wrinkle: GLP-1 drugs can improve fertility indirectly, particularly in women with PCOS or obesity-related ovulatory dysfunction, meaning some women become pregnant more easily while still on therapy than they may have anticipated — which is part of why proactive contraception planning and a clear conversation about conception timing is a relevant part of GLP-1 counseling for anyone of reproductive potential, not just people actively trying to conceive.

Breastfeeding Considerations

Whether GLP-1 drugs pass into breast milk in clinically significant amounts, and what effect that exposure might have on a nursing infant, is similarly under-studied compared to the drug's other safety data — current guidance generally recommends against use during breastfeeding given this data gap, following the same conservative approach applied to the pregnancy question.

Practical Takeaway

GLP-1 pregnancy warnings stem primarily from animal toxicity findings and a genuine absence of robust human pregnancy safety data, not from confirmed evidence of harm in humans — but that absence of confirming safety data is itself the reason for caution, not a basis for assuming safety. The recommended washout period before conception reflects both the drug's pharmacokinetics and the critical timing of early fetal development, and anyone of reproductive potential starting GLP-1 therapy should have an explicit conversation with their prescriber about conception timing and contraception.